Osteosarcoma is typically managed with neoadjuvant chemotherapy followed by surgical resection and adjuvant chemotherapy, resulting in a 5-year survival rate of 60-66% for high-grade cases.
This review provides a comprehensive overview of the pathogenesis, diagnosis, and multimodal treatment strategies for osteosarcoma, highlighting the role of neoadjuvant chemotherapy and limb-salvage surgery.
Osteosarcoma is the most common primary malignancy of bone in children and young adults. This tumor has a very heterogeneous genetic profile and lacks any consistent unifying event that leads to the pathogenesis of osteosarcoma. In this review, some of the important genetic events involved in osteosarcoma will be highlighted. Additionally, the clinical diagnosis of osteosarcoma will be discussed, as well as contemporary chemotherapeutic and surgical management of this tumor. Finally, the review will discuss some of the novel approaches to treating this disease.
Durfee et al. (Wed,) conducted a review in Osteosarcoma. Osteosarcoma is typically managed with neoadjuvant chemotherapy followed by surgical resection and adjuvant chemotherapy, resulting in a 5-year survival rate of 60-66% for high-grade cases.